Among the honored is James P. Allison, PhD, FAACR, who receives the AACR Award for Lifetime Achievement in Cancer Research. Allison’s seminal discovery of CTLA-4 as a negative regulator of T-cell activation revolutionized cancer immunotherapy. By elucidating the role of immune checkpoints, his research enabled the development of immune checkpoint inhibitors—therapies that have considerably improved cancer patient outcomes. These inhibitors effectively unleash the immune system to attack tumors, representing a paradigm shift that has transformed oncology. Allison’s contributions extend beyond scientific discovery to leadership and mentorship, solidifying his impact on the field.

In the realm of basic cancer science, Housheng Hansen He, PhD, recognized for Outstanding Achievement in Basic Cancer Research, has made pivotal strides in cancer epigenetics and RNA medicine. His work deciphers how chromatin accessibility and epigenomic landscapes dictate oncogenic transcriptional programs, illuminating mechanisms underlying tumor progression and therapeutic resistance. By integrating functional genomics with clinical insights, He’s research opens pathways toward RNA-based precision therapies, signaling a new era where epigenetic and post-transcriptional regulation are harnessed for cancer intervention.

John F. DiPersio, MD, PhD, awarded for excellence in blood cancer research, has notably advanced leukemia and stem cell biology. His development of stem cell mobilizing agents such as plerixafor and motixafortide has improved hematopoietic stem cell transplantation strategies. Additionally, DiPersio’s identification of AK1/2 signaling in graft-versus-host disease paved the way for JAK inhibitors like ruxolitinib, enhancing management of transplant complications. His elucidation of clonal evolution in acute myeloid leukemia is reshaping concepts of cancer relapse and informing innovative CAR T-cell therapies, broadening therapeutic options for blood cancers.

Chemistry’s contributions to cancer research are embodied by Cheryl H. Arrowsmith, PhD, recipient of the AACR Award for Outstanding Achievement in Chemistry in Cancer Research. Her pioneering studies of chromatin-associated proteins have catalyzed the development of chemical probes targeting epigenetic regulators, including protein methyltransferases and bromodomains. By advancing chemical biology tools, Arrowsmith has enabled detailed interrogation of cancer epigenetics, accelerating discovery of novel therapeutic targets. Her leadership in promoting open science through the Structural Genomics Consortium further amplifies the impact of her work by fostering collaborative innovation globally.

An outstanding figure in cancer education and training, Charles W.M. Roberts, MD, PhD, FAACR, is being honored with the AACR-Daniel D. Von Hoff Award. Roberts has transformed pediatric cancer research education through mentorship and the establishment of global initiatives, such as the Science of Childhood Cancer seminar series. His efforts have expanded training opportunities and cultivated a collaborative environment that nurtures future leaders in pediatric oncology research, ensuring sustained progress in addressing childhood cancers.

David L. Rimm, MD, PhD, honored with the AACR James S. Ewing-Thelma B. Dunn Award for pathology excellence, has revolutionized cancer diagnostics. By inventing the Automated Quantitative Analysis platform, Rimm introduced a fluorescence-based, high-precision method for quantifying protein expression directly in tissue specimens. His advancements in multiplexed and computational imaging strategies, combined with assay harmonization efforts for biomarkers such as PD-L1 and HER2, have directly contributed to precision oncology by refining diagnostic criteria and treatment stratification.

Antoni Ribas, MD, PhD, FAACR, awarded the AACR-Margaret Foti Award for Leadership and Extraordinary Achievements, epitomizes clinical and translational innovation. His pioneering melanoma research and contributions to developing immune checkpoint inhibitors like pembrolizumab have significantly influenced cancer immunotherapy. Ribas’ exploration of mechanisms behind immunotherapy resistance informs new combination therapies, underscoring his role in shaping contemporary cancer treatment paradigms and improving patient outcomes worldwide.

The AACR Team Science Award recognizes the Cancer Dependency Map (DepMap) Team from the Broad Institute for their comprehensive efforts to elucidate genetic dependencies across cancer types. Utilizing CRISPR screening, drug response profiling, and multiomic integration, the team has uncovered context-specific vulnerabilities, such as synthetic lethal interactions, enabling targeted therapeutic strategy development. Their open-access resource accelerates drug discovery and precision oncology research globally, exemplifying the power of collaborative, interdisciplinary science.

Elizabeth A. Platz, ScD, MPH, awarded for achievements in cancer epidemiology and prevention, has significantly advanced understanding of prostate cancer etiology and risk stratification. Her research linking intraprostatic inflammation to cancer risk and identifying telomere length as a prognostic biomarker informs both prevention and early detection strategies. Platz’s multidisciplinary leadership translates epidemiological insights into actionable cancer control policies, impacting population health at large.

Kenneth M. Murphy, MD, PhD, honored for outstanding contributions in cancer immunology, has elucidated key transcriptional mechanisms driving dendritic cell development and specialization. His pioneering research on BATF3-dependent dendritic cells has informed antigen presentation and T-cell priming processes essential for adaptive immunity. Murphy’s findings are foundational for enhancing immunotherapeutic approaches that harness dendritic cell-mediated antitumor responses.

Andrew P. Feinberg, MD, MPH, awarded the AACR-G.H.A. Clowes Award, has shaped our understanding of cancer epigenetics by identifying early DNA methylation abnormalities and global epigenomic reprogramming as drivers of tumor initiation and progression. Feinberg’s concept of epigenetic plasticity elucidates how cancer cells adapt and evolve, providing new avenues for detection and intervention that target the dynamic epigenome rather than static genetic mutations.

Dennis Lo, DM, DPhil, recognized with the AACR-Irving Weinstein Foundation Distinguished Lectureship, revolutionized noninvasive prenatal testing by discovering fetal DNA in maternal plasma. This breakthrough also catalyzed the development of liquid biopsy approaches in oncology, utilizing circulating tumor DNA for early cancer detection, monitoring, and personalized therapy selection. Lo’s visionary work continues to influence diagnostics and precision medicine across multiple clinical domains.

Luis A. Diaz Jr., MD, FAACR, recipient of the AACR-Joseph H. Burchenal Award, has pioneered biomarker-driven immunotherapies, demonstrating that tumors with mismatch repair deficiencies and microsatellite instability are particularly susceptible to immune checkpoint blockade. His clinical trials underscored immunotherapy’s transformative potential, including exceptional responses in rectal cancer, and advanced circulating tumor DNA-based minimal residual disease detection, promoting personalized management of solid tumors.

Ahmedin M. Jemal, DVM, PhD, honored for contributions to minority cancer research, has provided critical insights into cancer disparities through epidemiological analysis. His integrative studies of cancer incidence, mortality, and risk factors reveal demographic and geographic determinants, informing targeted prevention and control strategies that aim to reduce inequities in cancer burden across populations.

David C. Lyden, MD, PhD, awarded the AACR-Princess Takamatsu Memorial Lectureship, has elucidated mechanisms by which primary tumors facilitate metastasis through the establishment of pre-metastatic niches. His research on tumor-derived extracellular vesicles and bone marrow progenitors redefines metastatic biology and highlights systemic effects of tumors, such as thrombosis and metabolic alteration, providing novel targets to disrupt the metastatic cascade.

Kimberly Stegmaier, MD, FAACR, recognized for outstanding pediatric cancer research, has made foundational contributions to precision oncology in childhood cancers. Her genomic discoveries have unearthed key oncogenic drivers in pediatric leukemias and solid tumors, employing functional genomic screens to identify therapeutic vulnerabilities. Stegmaier’s leadership in large-scale collaborative initiatives like the Pediatric Cancer Dependency Map accelerates the translation of molecular insights into clinical interventions.

Eliezer M. Van Allen, MD, recipient of the AACR-Waun Ki Hong Award, has integrated cutting-edge cancer genomics and computational biology to decipher molecular determinants of therapeutic response and resistance. His work in melanoma and immunotherapy biomarkers exemplifies the fusion of artificial intelligence with clinical research, advancing personalized oncology and predictive modeling to enhance patient care.

Finally, Maryellen L. Giger, PhD, honored with the AACR-Women in Cancer Research Charlotte Friend Lectureship, has revolutionized cancer diagnostics through machine learning and quantitative imaging. Her innovative radiomics approaches extract multidimensional data from medical images, enabling noninvasive tumor characterization and prediction of treatment responses. As a mentor and advocate, Giger champions the advancement of women in science, fostering diversity and inclusion within the cancer research community.

The Pezcoller Foundation-AACR International Award recognizes Douglas R. Lowy, MD, FAACR, and John T. Schiller, PhD, FAACR, for their pioneering work in the molecular and immunologic basis of human papillomavirus (HPV) vaccines. Their engineering of virus-like particles and translational efforts have led to effective vaccines that dramatically reduce HPV-related cancers worldwide, illustrating the profound impact of basic science on global cancer prevention.

The 2026 AACR Annual Meeting stands as a monumental event celebrating the remarkable scientific achievements that are revolutionizing cancer research and patient care. Through honoring a diverse cohort of innovators—from molecular biologists and clinicians to chemists and epidemiologists—AACR highlights the integrated, multidisciplinary approach essential to conquering cancer. These awardees’ contributions not only deepen scientific understanding but also translate into tangible advances in diagnostics, therapeutics, and prevention strategies that promise to reshape the future landscape of oncology.

Subject of Research: Cancer research, including immunotherapy, epigenetics, leukemia, cancer diagnostics, epidemiology, pediatric oncology, cancer immunology, metastasis, molecular oncology, and cancer prevention.

Article Title: AACR Honors Pioneers Driving the Next Frontier in Cancer Research at 2026 Annual Meeting

News Publication Date: Not specified in the provided content

Web References:

• https://www.aacr.org/
• https://www.aacr.org/meeting/aacr-annual-meeting-2026/

References: Detailed award citations and biographies as provided by the AACR

Image Credits: Not provided

Keywords: AACR, Cancer Research, Immunotherapy, Epigenetics, Leukemia, Cancer Diagnostics, Cancer Epidemiology, Pediatric Oncology, Cancer Immunology, Metastasis, Molecular Oncology, HPV Vaccine, Precision Medicine

Resistance to immunotherapy presents one of the most formidable challenges in oncology today. While checkpoint inhibitors that unleash the immune system have revolutionized melanoma treatment, nearly half of patients who initially respond eventually suffer tumor recurrence. By closely examining genomic alterations, the UCLA team identified that relapsing tumors frequently carry copy-number variations—sections of the genome that are deleted or amplified—that specifically disrupt the tumor cells’ intrinsic pathways governing apoptosis, or programmed cell death. These genetic alterations blunt the cancer cells’ capacity to self-destruct when attacked by immune T cells, thereby fostering tumor survival and regrowth.

Historically, much cancer resistance research has concentrated on small-scale mutations such as point mutations. However, this groundbreaking work illuminates the pivotal role of large-scale genetic events like copy-number changes as efficient evolutionary tools for cancer adaptation. These mutations affect multiple genes simultaneously, especially those regulating apoptosis. This gene dosage imbalance cumulatively reshapes the tumor cell biology, endowing melanoma cells with enhanced capability to withstand immune-mediated insults triggered by checkpoint blockade therapies.

The investigators mapped tumor evolution by comparing samples obtained from melanoma patients at various time points: before treatment, after initial response, and at relapse following immune checkpoint inhibitor therapy. Using high-resolution genomic profiling and integrating published datasets of immunotherapy resistance genes, the UCLA team utilized both in vitro cell line models and mouse models to simulate and dissect the resistance mechanisms. Their comprehensive approach unmasked heterogeneous tumor subclones bearing distinct permutations of copy-number variants, illustrating that resistance mechanisms are not static but dynamically evolve under therapeutic pressure.

One of the most striking insights came from single-cell whole-genome sequencing technologies, which revealed that resistance-associated genetic aberrations already exist at low frequencies within tumors prior to immunotherapy. This finding challenges existing paradigms, suggesting that these resistant subclones undergo natural selection during treatment, eventually dominating the tumor landscape upon therapy-induced selective pressure. These data imply that monitoring tumor evolution at the single-cell level could be crucial for early identification of patients at risk of relapse and could inform more personalized treatment strategies.

In a transformative translational phase, the researchers explored whether pharmacologically lowering the apoptotic threshold of melanoma cells could restore their sensitivity to immune attack. Utilizing pro-apoptotic drugs on both cultured melanoma cells and mouse models, they observed reinstated immune-mediated tumor cell apoptosis. Most compellingly, when these drugs were administered in a mouse model after initial tumor regression induced by immunotherapy, tumor relapse was effectively prevented. This opens the door for adjuvant therapies that enhance cancer cell susceptibility to immune destruction, potentially extending the durability of immunotherapy responses.

Dr. Roger Lo, the senior author and a multidisciplinary professor at UCLA, underscored the significance of these findings: “Targeting the apoptotic machinery within residual tumor cells is a promising strategy to pre-empt resistance and prolong clinical benefit from checkpoint inhibitors. By intervening early in the evolution of resistant subpopulations, we aim to transform melanoma from a deadly cancer to a manageable chronic condition.”

The implications extend far beyond melanoma. Since immune checkpoint inhibitors have been adopted to treat a variety of cancers, understanding the genomic underpinnings of resistance could have broad impact. The UCLA team’s approach—integrating genomic analyses, single-cell sequencing, and mechanistic functional studies—provides a roadmap for deciphering resistance in other tumor types, illuminating new avenues for therapeutic innovation in the rapidly advancing field of cancer immunology.

Nevertheless, the study recognizes the need for larger patient cohorts and additional experimental models to validate and refine these insights. Future work will expand genomic analyses to dissect the full complexity of resistance evolution and will explore clinical trial designs that incorporate pro-apoptotic agents alongside immunotherapies. These trials could potentially shift paradigms by incorporating tumor evolutionary monitoring and tailored intervention strategies aimed at sustaining long-term remission.

The synergy of advanced genomic techniques and immunotherapy research exemplifies the scientific frontier in oncology, wherein deciphering the cancer genome’s large-scale changes can illuminate resistance pathways invisible to previous methodologies. This comprehensive perspective offers a compelling example of how molecular insights can drive the development of next-generation therapies that more effectively harness the immune system’s power against cancer.

In conclusion, this UCLA study adds a critical new dimension to the understanding of melanoma immunotherapy resistance. It reveals that genomic copy-number variants serve as a stealthy evolutionary mechanism, endowing tumors with a multi-faceted arsenal to defy immune eradication. The prospect of pharmacological manipulation of apoptotic pathways to thwart this resistance offers an exciting and tangible hope for improving survival outcomes in patients plagued by this aggressive skin cancer.

Subject of Research: Melanoma resistance mechanisms to immunotherapy and potential therapeutic strategies to overcome it.

Article Title: (Not provided)

News Publication Date: (Not provided)

Web References:

• UCLA Health Jonsson Comprehensive Cancer Center: https://www.uclahealth.org/cancer
• Published study in Immunity: https://www.cell.com/immunity/fulltext/S1074-7613(25)00431-5
• DOI link: http://dx.doi.org/10.1016/j.immuni.2025.10.001

References:
A study funded by the National Institutes of Health, V Foundation for Cancer Research, Melanoma Research Alliance, Melanoma Research Foundation.

Image Credits: (Not provided)

Keywords: Melanoma, Skin cancer, Cancer, Cancer research, Immunology, Cancer immunotherapy, Immunotherapy

The study, published in the esteemed journal Nature Communications, features a breakthrough three-gene model referred to as the “MANAscore.” This innovative model allows researchers to pinpoint tumor-infiltrating immune cells that are susceptible to the effects of immune checkpoint inhibitors. The study’s first author, Zhen Zeng, Ph.D., a bioinformatics research associate at the Kimmel Cancer Center, explains that this new model not only identifies the targeted immune cells but also provides insights into variations among patients’ responses to cancer immunotherapy.

Study participants exhibited diverse responses to immune checkpoint therapy, making it imperative to understand the cellular factors contributing to these differences. The MANAscore model significantly streamlines the identification process of T cells activated by immunotherapy, bypassing the lengthy and costly methods traditionally employed. This advancement is pivotal, as it lays a foundation for future research to uncover better biomarkers and molecular targets tailored for advanced cancer immunotherapies.

The mechanism of immune checkpoint inhibitors revolves around the activation of T cells, specifically the tumor-killing variety, which is commonly rendered inactive by the PD-1 protein. By blocking PD-1, these therapies reactivate the T cells, empowering the immune system to recognize and combat tumors more effectively. However, the heterogeneity in patient immune responses remains a challenge for researchers and clinicians alike. Understanding why certain patients respond favorably to these therapies while others do not is critical for advancing cancer treatments.

Traditional methods for identifying tumor-active T cells have been painstakingly complex and labor-intensive, often requiring extensive resources and time. The MANAscore model simplifies this process by utilizing a mere three genes, contrasting starkly with other models that demand up to 200 genes for the same task. The ease of use and straightforward nature of this model could lead to rapid adoption in clinical settings, potentially improving patient care and outcomes.

In their analysis, the study team identified a key distinction between the tumor-activated T cells in patients who responded to the immune therapy and those who did not. Patients displaying a positive response tended to have a higher percentage of stem-like memory T cells. These stem-like characteristics suggest a greater capacity for proliferation and longevity, allowing T cells to generate a substantial anti-tumor response when required.

The research also highlighted the importance of cellular dynamics within the tumor microenvironment. Understanding how T cells interact with other immune cells, such as regulatory T cells, provides valuable insight into the nuanced immune responses at play during cancer therapy. Zeng expresses the team’s ambition to apply the MANAscore model to spatial data, determining whether the interactions between tumor-targeting T cells and adjacent cells influence clinical outcomes.

For now, the team is focused on translating their research into a practical clinical test. By employing multispectral immunofluorescence panels, they aim to identify the three-gene signature of T cells responsive to immunotherapy. This clinical tool could serve as an invaluable resource for oncologists, offering a reliable method to evaluate patients’ potential responses to immunotherapies based on their unique immune profiles.

In collaboration with various laboratories across the country, the research group is also exploring if the MANAscore model is applicable to diverse cancer types. A comprehensive database aggregating single-cell sequencing data from different cancers is being analyzed, which will aid in pinpointing specific T cell characteristics related to responsiveness in various cancer contexts.

As the team continues to refine and validate their model, they are fueled by the promising potential of translating their findings into real-world applications. The identification of T cell populations that can effectively target tumors could pave the way for future combination therapies that enhance the efficacy of current immunotherapy treatments.

While the research holds immense promise for lung cancer patients, it also represents a significant step forward in the broader field of cancer treatment. The insights gleaned from this study could catalyze new research directions, ultimately leading to better understanding and more effective interventions across a multitude of cancer types.

In conclusion, the work of Zhen Zeng, Kellie Smith, and their colleagues exemplifies the synergy of cutting-edge technology and biological research in combatting one of humanity’s most challenging health crises. Their discoveries not only advance scientific understanding but also hold the potential for tangible enhancements in clinical practice, ushering in a new era of personalized cancer therapy designed to outsmart tumors and empower patients in their fight against cancer.

Subject of Research: Tumor-fighting immune cells in lung cancer
Article Title: Johns Hopkins Researchers Develop New Computer Model to Enhance Immune Checkpoint Therapy Efficacy
News Publication Date: February 3
Web References: Johns Hopkins Kimmel Cancer Center, Bloomberg~Kimmel Institute for Cancer Immunotherapy
References: Nature Communications journal article
Image Credits: Johns Hopkins Medicine

Keywords: Cancer therapy, Immune checkpoint inhibitors, T cells, Lung cancer, MANAscore, Immunotherapy, Cancer research, Computer modeling, Biomarkers, Personalized medicine.